<i>CYP2A6</i> and <i>ERCC1</i> polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients

Park, S R,Kong, S-Y,Nam, B-H,Choi, I J,Kim, C G,Lee, J Y,Cho, S J,Kim, Y W,Ryu, K W,Lee, J H,Rhee, J,Park, Y-I,Kim, N K Nature Publishing Group 2011 The British journal of cancer Vol.104 No.7

<P><B>Background:</B></P><P>We evaluated the association between polymorphisms of cytochrome P450 2A6 (<I>CYP2A6</I>)/excision repair cross-complementation group 1 (<I>ERCC1</I>)/X-ray repair cross-complementing group 1(<I>XRCC1</I>) and treatment outcomes of metastatic gastric cancer (MGC) patients treated with S-1/cisplatin.</P><P><B>Methods:</B></P><P>Among MGC patients (<I>n</I>=108), who received S-1 (40 mg m<SUP>−2</SUP> b.i.d., days 1–14) and cisplatin (60 mg m<SUP>−2</SUP>, day 1) every 3 weeks, we analysed the wild-type allele (<I>W</I>) and variants (<I>V</I>) of <I>CYP2A6</I> (<I>*4</I>, <I>*7, *9, *10</I>), and the polymorphisms of <I>ERCC1</I> (rs11615, rs3212986) and <I>XRCC1</I> (rs25487).</P><P><B>Results:</B></P><P>Patients having fewer <I>CYP2A6</I> variants had better response rates (<I>W</I>/<I>W vs W</I>/<I>V</I> other than <I>*1/*4 vs V</I>/<I>V</I> or <I>*1/*4</I>=66.7 <I>vs</I> 58.3 <I>vs</I> 32.3% <I>P</I>=0.008), time to progression (TTP) (7.2 <I>vs</I> 6.1 <I>vs</I> 3.5 months, <I>P</I>=0.021), and overall survival (23.2 <I>vs</I> 15.4 <I>vs</I> 12.0 months, <I>P</I>=0.004). <I>ERCC1 19442C</I>><I>A</I> (rs3212986) was also associated with response rate (<I>C/C</I>, 46.7% <I>vs C/A</I>, 55.3% <I>vs A/A</I>, 87.5%) (<I>P</I>=0.048) and TTP (4.4 <I>vs</I> 7.6 <I>vs</I> 7.9 months) (<I>P</I>=0.012). Patients carrying both risk genotypes of <I>CYP2A6</I> (<I>V</I>/<I>V</I> or <I>1/*4</I>) and <I>ERCC1 19442C</I>><I>A</I> (<I>C/C</I>) <I>vs</I> those carrying none showed an adjusted odds ratio of 0.113 (<I>P</I>=0.004) for response, and adjusted hazard ratios of 3.748 (<I>P</I>=0.0001) for TTP and 2.961 (<I>P</I>=0.006) for death.</P><P><B>Conclusion:</B></P><P>Polymorphisms of <I>CYP2A6</I> and <I>ERCC1 19442C</I>><I>A</I> correlated with the efficacy of S-1/cisplatin.</P>

Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis

Hur, H,Kim, N K,Kim, H G,Min, B S,Lee, K Y,Shin, S J,Cheon, J H,Choi, S H Nature Publishing Group 2012 The British journal of cancer Vol.106 No.1

<P><B>Background:</B></P><P>This study aims to evaluate the effectiveness of adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided neoadjuvant chemotherapy for increasing resectability in patients with unresectable colorectal liver metastasis.</P><P><B>Patients and methods:</B></P><P>Patients were randomised into two groups: Group A was treated by conventional chemotherapy regimen and Group B was treated by chemotherapy regimen according to the ATP-CRA. Three chemotherapeutic agents (5-fluorouracil, oxaliplatin and irinotecan) were tested by ATP-CRA and more sensitive agents were selected. Either FOLFOX or FOLFIRI was administered. Between Group A and B, treatment response and resectability were compared.</P><P><B>Results:</B></P><P>Between November 2008 and October 2010, a total 63 patients were randomised to Group A (<I>N</I>=32) or Group B (<I>N</I>=31). FOLFOX was more preferred in Group A than in Group B (26 out of 32 (81.3%) <I>vs</I> 20 out of 31 (64.5%)). Group B showed better treatment response than Group A (48.4% <I>vs</I> 21.9%, <I>P</I>=0.027). The resectability of hepatic lesion was higher in Group B (35.5% <I>vs</I> 12.5%, <I>P</I>=0.032). Mean duration from chemotherapy onset to the time of liver resection was 11 cycles (range 4–12) in Group A and 8 cycles (range 8–16) in Group B.</P><P><B>Conclusion:</B></P><P>This study showed that tailored-chemotherapy based on ATP-CRA could improve the treatment response and resectability in initially unresectable colorectal liver metastasis.</P>

한국의 HIV-1 감염의 분자역학

이주실,김은영,남정구,기미경,최병선,김성순,강춘,구본기,신영오 국립보건연구원 1998 국립보건원보 Vol.35 No.-

한국인 Long Term Non Progressors로부터 분리된 HIV-1 env 및 nef 유전자와 이들의 면역 유전학적 특성 분석에 의한 질병진전 요인 규명

이주실,강춘,김성순,박근용,고운영,기미경,최병선,남정구,서순덕,이성래,구본기,박혜경,도경미,김태규,최희백,조현일,김요숙,김지영,이해정,안수진 국립보건연구원 1999 국립보건원보 Vol.36 No.-

국내 HIV/AIDS 발견이후 HIV 유행주의 분자역학적 변이 분석

이주실,김성순,남정구,전수경,변승옥,최병선,박미선,김옥진,서순덕 국립보건연구원 2000 국립보건원보 Vol.37 No.-

여중생의 월경전증후군과 우울에 관한 서술적 조사연구

최고은,이경은,양지은,안수빈,김영우,최슬기,최혜준,김나현,간보선 이화여자대학교 간호과학대학 2015 이화간호학회지 Vol.- No.49

Objectives : The purpose of this research is to analyze the frequency, clinical characteristics of premenstrual syndrome, and the relationship between premenstrual syndrome and depression in middle school girls. Methods : Subjects of the research were 241 students recruited from 3 women's middle schools in Seoul, Korea. The questionnaires were composed of clinical characteristics of menstruation, Premenstrual Symptom Screening Tool, and Center for Epic Studies Depression Scale. Data were statistically analyzed by Chi-square, t-test, ANOVA, and Scheffe test. Results : The proportion of no/mild premenstrual syndrome was 83.4%, moderate to severe premenstrual syndrome was 12.9% and premenstrual dysphoric disorder was 3.7%. Premenstrual syndrome proportion was higher in severe menstruation pain group(χ2=11.956, p=.008) and depression group (χ2=50.85, p<.001). The mean of depression score was 11.61±9.09. Menstrual pain (F=4.59, p=.004) and premenstrual syndrome (F=68.81, p<.001) were found to be significant in depression. Conclusions : We identified that 16.6% of middle school girls suffered from premenstrual syndrome. We also analyzed that the clinical characteristics of menstruation pain and depression were related to premenstrual syndrome. And there was a relationship between depression and premenstrual syndrome. Accordingly, we can think of applying nursing interventions on menstruation pain and depression in middle school girls who are undergoing premenstrual syndrome.

Clinical and histopathological study of Charcot-Marie-Tooth neuropathy with a novel S90W mutation in BSCL2.

Choi, B-O,Park, M-H,Chung, K W,Woo, H-M,Koo, H,Chung, H-K,Choi, K-G,Park, K D,Lee, H J,Hyun, Y S,Koo, S K Oxford University Press 2013 Neurogenetics Vol.14 No.1

<P>The objective of the study was to investigate the disease-causing mutation in an autosomal dominant Charcot-Marie-Tooth disease type 2 family and examine the clinical and histopathological evaluation. We enrolled a family of Korean origin with axonal Charcot-Marie-Tooth disease neuropathy (FC305; 13 males, six females) and applied genome-wide linkage analysis. Whole exome sequencing was performed for two patients. In addition, sural nerve biopsies were obtained from two patients. Through whole exome sequencing, we identified an average of 20,336 coding variants from two patients. We also found evidence of linkage mapped to chromosome 11p11-11q13.3 (LOD score of 3.6). Among these variants in the linkage region, we detected a novel p.S90W mutation in the Berardinelli-Seip congenital lipodystrophy 2 (BSCL2) gene, after filtering 31 Korean control exomes. Our p.S90W patients had frequent sensory disturbances, pyramidal tract signs, and predominant right thenar muscle atrophy in comparison with reported p.S90L patients. The phenotypic spectra were wide and demonstrated intrafamilial variability. Two patients with different clinical features underwent sural nerve biopsies; the myelinated fiber densities were increased slightly in both patients, which differed from two previous case reports of BSCL2 mutations (p.S90L and p.N88S). This report expands the variability of the clinical spectrum associated with the BSCL2 gene and describes the first family with the p.S90W mutation.</P>

The long-term relationship between dietary pantothenic acid (vitamin B₅) intake and C-reactive protein concentration in adults aged 40 years and older

Jung, S.,Kim, M.K.,Choi, B.Y. Elsevier 2017 Nutrition, metabolism, and cardiovascular diseases Vol.27 No.9

<P><B>Abstract</B></P> <P><B>Background and aims</B></P> <P>Low-grade inflammation, represented by minor C-reactive protein (CRP) elevation, has a critical role in the early stages of atherosclerosis, and pantothenic acid (PA) may have an antioxidant effect in inflammatory process. However, the long-term relationship between PA intake and CRP has not yet been studied. The objective of the present study was to evaluate the long-term relationship of PA intake to CRP concentration in healthy adults aged 40 years or older living in a rural area of South Korea.</P> <P><B>Methods and Results</B></P> <P>A total of 908 subjects (349 men, 559 women) with repeated data on dietary PA intake and CRP concentration were included in the final analysis. To represent the long-term effect of PA intake, both PA intake at the baseline and average PA intake were used as the exposure, and CRP concentration at the third visit and its change from the baseline to the third visit were used as the outcome. After adjustment for potential confounders, a significant inverse relationship between PA intake and CRP concentration at the third visit was observed (<I>P</I> for trend = 0.001, <I>β</I> = −0.07 (<I>P</I>-value = 0.001) for PA <SUB>baseline</SUB>; <I>P</I> for trend = <0.0001, <I>β</I> = −0.11 (<I>P</I>-value = 0.0004) for PA <SUB>average (baseline, 2nd, 3rd)</SUB>). Higher PA intake was significantly related to lower or attenuated increase in CRP concentration (<I>P</I> for trend = 0.002, <I>β</I> = −0.24 (<I>P</I>-value = 0.002) for PA <SUB>baseline</SUB>; <I>P</I> for trend = 0.001, <I>β</I> = −0.35 (<I>P</I>-value = 0.001) for PA <SUB>average (baseline, 2nd, 3rd)</SUB>).</P> <P><B>Conclusions</B></P> <P>In conclusion, dietary PA intake was inversely related to subsequent CRP concentration in both men and women aged 40 years or older in South Korea.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Higher baseline and average PA intakes were significantly related to lower CRP concentration at the end of follow-up. </LI> <LI> Higher average PA intakes were significantly related to lower CRP concentration or attenuated increase in CRP concentration. </LI> <LI> PA should not be overlooked in regard to its effects on inflammation, because it might have an antioxidant effect. </LI> </UL> </P>

Control of electrical properties and gate bias stress stability in solution-processed a-IZO TFTs by Zr doping

Choi, W.S.,Jo, H.,Kwon, M.S.,Jung, B.J. Elsevier 2014 Current Applied Physics Vol.14 No.12

Zr-doped indium zinc oxide (IZO) thin film transistors (TFTs) are fabricated via a solution process with different Zr doping ratios. The addition of Zr suppressed the carrier concentration in the IZO films, which was confirmed by Hall Effect measurements. As the amount of Zr was increased in the oxide active layer of TFTs, the subthreshold swing (S.S) reduced, the ON/OFF ratio improved, and the threshold voltage (V<SUB>th</SUB>) shifted positively. Moreover, the starting points of the ON state for TFTs near the point zero gate voltage could be controlled by the addition of Zr. The 0.3% Zr-doped IZO TFT exhibited a high saturation mobility of 7.0 cm<SUP>2</SUP> V<SUP>-1</SUP> s<SUP>-1</SUP>, ON/OFF ratio of 2.6 x 10<SUP>6</SUP> and S.S of 0.57 V/decade compared the IZO TFT with 10.1 cm<SUP>2</SUP> V<SUP>-1</SUP> s<SUP>-1</SUP>, 1.7 x 10<SUP>6</SUP> and 0.75 V/decade. The Zr effect of the gate bias stability was examined. Zr-doped IZO TFTs were relatively unstable under a positive bias stress (PBS), whereas they showed good stability at a negative bias stress (NBS). The gate bias stability of the oxide TFTs were compared with the extracted parameters through a stretched-exponential equation. The characteristic trapping time under NBS of 0.3% Zr-doped IZO TFTs was improved from 8.3 x 10<SUP>4</SUP> s for the IZO TFT to 3.1 x 10<SUP>5</SUP> s.

<i>S100A9</i> and <i>EGFR</i> gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy

Kim, W. T.,Kim, J.,Yan, C.,Jeong, P.,Choi, S. Y.,Lee, O. J.,Chae, Y. B.,Yun, S. J.,Lee, S. C.,Kim, W. J. Oxford University Press 2014 Annals of Oncology Vol.25 No.5

<P>In our previous gene expression profile analysis, IL1B, S100A8, S100A9, and EGFR were shown to be important mediators of muscle invasive bladder cancer (MIBC) progression. The aim of the present study was to investigate the ability of these gene signatures to predict disease progression after chemotherapy in patients with locally recurrent or metastatic MIBC. Patients with locally advanced MIBC who received chemotherapy were enrolled. The expression signatures of four genes were measured and carried out further functional analysis to confirm our findings. Two of the four genes, S100A9 and EGFR, were determined to significantly influence disease progression (P = 0.023, 0.045, respectively). Based on a receiver operating characteristic curve, a cut-off value for disease progression was determined. Patients with the good-prognostic signature group had a significantly longer time to progression and cancer-specific survival time than those with the poor-prognostic signature group (P < 0.001, 0.042, respectively). In the multivariate Cox regression analysis, gene signature was the only factor that significantly influenced disease progression [hazard ratio: 4.726, confidence interval: 1.623-13.763, P = 0.004]. In immunohistochemical analysis, S100A9 and EGFR positivity were associated with disease progression after chemotherapy. Protein expression of S100A9/EGFR showed modest correlation with gene expression of S100A9/EGFR (r = 0.395, P = 0.014 and r = 0.453, P = 0.004). Our functional analysis provided the evidence demonstrating that expression of S100A9 and EGFR closely associated chemoresistance, and that inhibition of S100A9 and EGFR may sensitize bladder tumor cells to the cisplatin-based chemotherapy. The S100A9/EGFR level is a novel prognostic marker to predict the chemoresponsiveness of patients with locally recurrent or metastatic MIBC.</P>